Francesco Piazza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11785805/publications.pdf

Version: 2024-02-01

212478 286692 2,213 82 28 citations h-index papers

43 g-index 84 84 84 3462 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation. Haematologica, 2022, 107, 868-876.	1.7	31
2	Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi. Journal of Clinical Oncology, 2022, 40, 4060-4070.	0.8	8
3	Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies. PLoS ONE, 2021, 16, e0247717.	1.1	10
4	Kinetic theory of hyaluronan cleavage by bovine testicular hyaluronidase in standard and crowded environments. Biochimica Et Biophysica Acta - General Subjects, 2021, 1865, 129837.	1,1	5
5	Targeting Protein Kinases in Blood Cancer: Focusing on CK1 \hat{i} ± and CK2. International Journal of Molecular Sciences, 2021, 22, 3716.	1.8	18
6	Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients. Frontiers in Oncology, 2021, 11, 682658.	1,3	2
7	Limbic Encephalitis with HU-Antibodies in T-cell Anaplastic Lymphoma. A Case Report. Applied Sciences (Switzerland), 2021, 11, 6548.	1.3	2
8	Mechanisms for transient localization in a diatomic nonlinear chain. Communications in Nonlinear Science and Numerical Simulation, 2021, 102, 105913.	1.7	3
9	Long-Range Photon Fluctuations Enhance Photon-Mediated Electron Pairing and Superconductivity. Physical Review Letters, 2021, 127, 177002.	2.9	13
10	Protein Kinase $\text{CK1}\hat{l}\pm$ Sustains B-Cell Receptor Signaling in Mantle Cell Lymphoma. Frontiers in Oncology, 2021, 11, 733848.	1.3	4
11	Targeting of HSP70/HSF1 Axis Abrogates In Vitro Ibrutinib-Resistance in Chronic Lymphocytic Leukemia. Cancers, 2021, 13, 5453.	1.7	6
12	Interferon-free compared to interferon-based antiviralÂregimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia, 2020, 34, 1462-1466.	3.3	30
13	New responsibilities for aged kinases in Bâ€lymphomas. Hematological Oncology, 2020, 38, 3-11.	0.8	8
14	Nonequilibrium diagrammatic approach to strongly interacting photons. Physical Review A, 2020, 102, .	1.0	6
15	<p>Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia</p> . OncoTargets and Therapy, 2020, Volume 13, 9679-9688.	1.0	19
16	Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature. Hematological Oncology, 2020, 38, 823-826.	0.8	16
17	A case of "double hit―mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib. Annals of Hematology, 2020, 99, 2715-2717.	0.8	2
18	Polyethylene glycol crowding effect on hyaluronidase activity monitored by capillary electrophoresis. Analytical and Bioanalytical Chemistry, 2020, 412, 4195-4207.	1.9	4

#	Article	IF	Citations
19	Actionable Strategies to Target Multiple Myeloma Plasma Cell Resistance/Resilience to Stress: Insights From "Omics―Research. Frontiers in Oncology, 2020, 10, 802.	1.3	3
20	Crowding-Induced Uncompetitive Inhibition of Lactate Dehydrogenase: Role of Entropic Pushing. Journal of Physical Chemistry B, 2020, 124, 727-734.	1.2	8
21	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. HemaSphere, 2020, 4, e395.	1.2	4
22	Prosurvival autophagy is regulated by protein kinase CK1 alpha in multiple myeloma. Cell Death Discovery, 2019, 5, 98.	2.0	22
23	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. Hematological Oncology, 2019, 37, 508-512.	0.8	13
24	HSP70/HSF1 axis, regulated <i>via</i> a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemia. International Journal of Cancer, 2019, 145, 3089-3100.	2.3	32
25	Cavity-Quantum-Electrodynamical Toolbox for Quantum Magnetism. Physical Review Letters, 2019, 122, 113603.	2.9	47
26	Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 678-685.e4.	0.2	25
27	Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas. Oncologist, 2019, 24, e720-e729.	1.9	52
28	Severe infections unrelated to neutropenia impact on overall survival in multiple myeloma patients: results of a single centre cohort study. British Journal of Haematology, 2019, 186, e13-e17.	1.2	3
29	Diffusion-influenced reactions on non-spherical partially absorbing axisymmetric surfaces. Physical Chemistry Chemical Physics, 2019, 21, 25896-25906.	1.3	9
30	In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. Cancers, 2019, 11, 1939.	1.7	39
31	Peripheral nervous system involvement in lymphomas. Journal of the Peripheral Nervous System, 2019, 24, 5-18.	1.4	44
32	Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. Human Pathology, 2019, 85, 251-259.	1.1	6
33	Wavelet imaging of transient energy localization in nonlinear systems at thermal equilibrium: The case study of Nal crystals at high temperature. Physical Review B, 2019, 99, .	1.1	18
34	Hopping in the Crowd to Unveil Network Topology. Physical Review Letters, 2018, 120, 158301.	2.9	20
35	The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma. Blood Cancer Journal, 2018, 8, 20.	2.8	19
36	Catalysis by Metallic Nanoparticles in Solution: Thermosensitive Microgels as Nanoreactors. Zeitschrift Fur Physikalische Chemie, 2018, 232, 773-803.	1.4	42

#	Article	IF	CITATIONS
37	Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia. Hematological Oncology, 2018, 36, 366-369.	0.8	6
38	Rituximab, bendamustine and cytarabine (Râ€BAC) in patients with relapsedâ€refractory aggressive Bâ€cell lymphoma. American Journal of Hematology, 2018, 93, E386-E389.	2.0	4
39	Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation. Blood Cancer Journal, 2018, 8, 51.	2.8	20
40	Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance. International Journal of Molecular Sciences, 2018, 19, 1512.	1.8	16
41	Dabigatran in ibrutinibâ€treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases. Hematological Oncology, 2018, 36, 801-803.	0.8	4
42	CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. Current Cancer Drug Targets, 2018, 18, 608-616.	0.8	10
43	Superradiant Topological Peierls Insulator inside an Optical Cavity. Physical Review Letters, 2017, 118, 073602.	2.9	66
44	Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. British Journal of Haematology, 2017, 178, 81-93.	1.2	25
45	Aberrant expression of <scp>CD</scp> 10 and <scp>BCL</scp> 6 in mantle cell lymphoma. Histopathology, 2017, 71, 769-777.	1.6	29
46	Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients. European Journal of Cancer, 2017, 72, 103-111.	1.3	29
47	Peripheral neuropathies in chronic lymphocytic leukemia: a single center experience on 816 patients. Haematologica, 2017, 102, e140-e143.	1.7	17
48	Epidemiology and risk factors of invasive fungal infections in a large cohort of patients with chronic lymphocytic leukemia. Hematological Oncology, 2017, 35, 925-928.	0.8	19
49	Role of protein kinases $CK1\hat{l}\pm$ and $CK2$ in multiple myeloma: regulation of pivotal survival and stress-managing pathways. Journal of Hematology and Oncology, 2017, 10, 157.	6.9	32
50	Inactivation of CK1 \hat{l} ± in multiple myeloma empowers drug cytotoxicity by affecting AKT and \hat{l} 2-catenin survival signaling pathways. Oncotarget, 2017, 8, 14604-14619.	0.8	30
51	Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties. Oncotarget, 2017, 8, 53053-53067.	0.8	27
52	<i>STAT3</i> mutation impacts biological and clinical features of T-LGL leukemia. Oncotarget, 2017, 8, 61876-61889.	0.8	67
53	Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases. Oncotarget, 2017, 8, 110727-110731.	0.8	23
54	Macroscopic Transport Equations in Many-Body Systems from Microscopic Exclusion Processes in Disordered Media: A Review. Frontiers in Physics, 2016, 4, .	1.0	5

#	Article	IF	CITATIONS
55	Reaction rate of a composite core–shell nanoreactor with multiple nanocatalysts. Physical Chemistry Chemical Physics, 2016, 18, 20758-20767.	1.3	18
56	Conformation-controlled binding kinetics of antibodies. Scientific Reports, 2016, 6, 18976.	1.6	23
57	Theory of diffusion-influenced reactions in complex geometries. Physical Chemistry Chemical Physics, 2016, 18, 15950-15954.	1.3	31
58	Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica, 2015, 100, e515-e518.	1.7	48
59	Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. Oncotarget, 2015, 6, 42130-42149.	0.8	39
60	Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 612-620.e5.	0.2	26
61	Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. Oncotarget, 2015, 6, 6544-6552.	0.8	31
62	Umklapp Superradiance with a Collisionless Quantum Degenerate Fermi Gas. Physical Review Letters, 2014, 112, 143003.	2.9	78
63	Quantum kinetics of ultracold fermions coupled to an optical resonator. Physical Review A, 2014, 90, .	1.0	32
64	Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells. Haematologica, 2014, 99, 1826-1833.	1.7	21
65	Novel players in multiple myeloma pathogenesis: Role of protein kinases CK2 and GSK3. Leukemia Research, 2013, 37, 221-227.	0.4	28
66	Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity. Journal of Hematology and Oncology, 2013, 6, 78.	6.9	46
67	Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood, 2013, 121, 3843-3854.	0.6	85
68	Protein Kinase CK2 Inhibition Down Modulates the NF-κB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. PLoS ONE, 2013, 8, e75280.	1.1	75
69	Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress–Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response. Clinical Cancer Research, 2012, 18, 1888-1900.	3.2	71
70	Signalling Molecules as Selective Targets for Therapeutic Strategies in Multiple Myeloma. , 2012, , 87-108.		0
71	Serine-Threonine Protein Kinases CK1, CK2 and GSK3 in Normal and Malignant Haematopoiesis. Current Signal Transduction Therapy, 2011, 6, 88-98.	0.3	4
72	Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. BMC Cancer, 2010, 10, 526.	1.1	39

#	Article	IF	CITATIONS
73	3-(2,4-Dichlorophenyl)-4-(1-methyl-1 <i>H</i> i>indol-3-yl)-1 <i>H</i> -pyrrole-2,5-dione (SB216763), a Glycogen Synthase Kinase-3 Inhibitor, Displays Therapeutic Properties in a Mouse Model of Pulmonary Inflammation and Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 785-794.	1.3	36
74	A dynamical study of antibody–antigen encounter reactions. Physical Biology, 2007, 4, 172-180.	0.8	20
75	Diffusion-Limited Unbinding of Small Peptides from PDZ Domains. Journal of Physical Chemistry B, 2007, 111, 11057-11063.	1.2	5
76	Multiple myeloma plasma cells show different chemokine receptor profiles at sites of disease activity. British Journal of Haematology, 2007, 138, 594-602.	1.2	44
77	Inhibition of Leukocyte Elastase, Polymorphonuclear Chemoinvasion, and Inflammation-Triggered Pulmonary Fibrosis by a 4-Alkyliden-β-lactam with a Galloyl Moiety. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 539-546.	1.3	21
78	Functional Dynamics of PDZ Binding Domains: A Normal-Mode Analysis. Biophysical Journal, 2005, 89, 14-21.	0.2	124
79	Molecular therapeutic approaches to acute myeloid leukemia: targeting aberrant chromatin dynamics and signal transduction. Expert Review of Anticancer Therapy, 2004, 4, 387-400.	1,1	6
80	The theory of APL. Oncogene, 2001, 20, 7216-7222.	2.6	103
81	Some new 1,2,3,4-tetrahydroquinoline derivatives. Il Farmaco, 2000, 55, 47-50.	0.9	2
82	The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. Journal of Clinical Investigation, 1999, 104, 115-121.	3.9	134